---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046065"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:14:07.834451+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAtla reports Q4 net loss $14.9M, cuts workforce 30% to extend runway to 1H 2026 clinical readouts

## Summary
- Net loss $14.9M in Q4 2024 vs $26.9M Q4 2023; cash $49.0M at year-end vs $111.5M.
- Workforce reduction of over 30%; estimated $0.5-$0.6M in severance costs mostly in Q2 2025.
- BA3182 (CAB-EpCAM x CAB-CD3) Phase 1 dose escalation ongoing; data readout mid-2025; expansion data 1H 2026.
- Mecbotamab vedotin (CAB-AXL-ADC): 66% 1-year OS, 58% 2-year OS in mKRAS NSCLC; median OS not reached.
- Ozuriftamab vedotin (CAB-ROR2-ADC): 45% ORR (confirmed/unconfirmed) in HPV+ SCCHN; partnering discussions Q1 2025.

## SEC filing metadata
- accession: 0000950170-25-046065
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017025046065/0000950170-25-046065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017025046065/bcab-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046065
- JSON: https://secwatch.observer/filing/0000950170-25-046065.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.